Ignite Creation Date:
2024-05-06 @ 2:02 PM
Last Modification Date:
2024-10-26 @ 1:23 PM
Study NCT ID:
NCT04190550
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-04
First Post:
2019-12-06
Brief Title:
Testing the Addition of an Anti-cancer Drug Navtemadlin to the Usual Treatments Cytarabine and Idarubicin in Patients With Acute Myeloid Leukemia
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Organization Data
Organization:
National Cancer Institute NCI
Class:
NIH
Study ID:
NCI-2019-08137
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Cancer Institute NCI
Lead Sponsor Class:
NIH
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None